Status
Acquired by Gilead Sciences on February 22, 2011
Funding Received
$92 Million in 4 Rounds from 6 Investors
Headquarters:
Seattle, WA
Description:
Calistoga Pharmaceuticals develops therapeutic oral medicines for patients suffering from cancer and inflammatory diseases.
Founders:
Neill Giese
Categories:
Medical, Pharmaceuticals, Biotechnology
Website:
http://www.calistogapharma.com

Company Details

Update
Founded:
2006
Employees:
None found in CrunchBase

Calistoga Pharmaceuticals, Inc. is the leader in developing innovative oral medicines targeting selected isoforms of the PI3 kinase pathway to improve the health of patients with cancer and inflammatory diseases.

The PI3K pathway is a critical cellular pathway involved in cell survival and immune cell activation. Calistoga Pharmaceuticals' small-molecule therapeutic candidates inhibit specific isoforms of the PI3K pathway, providing a targeted treatment approach designed to maximize clinical outcome and limit unwanted side effects.

Calistoga Pharmaceuticals' lead product, CAL-101, an oral delta-isoform selective PI3K inhibitor, has demonstrated promising clinical responses in patients with B-cell malignancies and is currently being evaluated in multiple clinical trials. In addition to CAL-101, Calistoga Pharmaceuticals' product development pipeline includes other selective PI3K inhibitors in early preclinical development or ready for initial clinical trials in patients with cancer or inflammatory diseases.

Past Team (4)

Update

Investors (6)

Update

Offices/Locations (1)

Update
  • Office

    2101 4th Avenue, Suite 1960

    Seattle, WA 98121

    USA

Images (1)

Update
  • 9baa7e2184b4a757512925a20c51ce5c